Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an investigational adjunctive therapy designed to extend AF treatment beyond the hospital and into the home.

此次融资紧随经过同行评审的NeuroPulse试点研究结果，并支持Rhyvive™的关键性试验；Rhyvive™是一种在研的辅助疗法，旨在将心房颤动（AF）治疗从医院延伸至家庭环境。

LOS ANGELES

洛杉矶

,

，

Oct. 29, 2026

2026年10月29日

/PRNewswire/ --

/美通社/ --

StimCardio

StimCardio

, a clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation (AF), today announced the closing of its oversubscribed $30 million Series A financing led by John Slump's family office, Metis Medtech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors.

，一家处于临床阶段的医疗器械公司，致力于开发用于心房颤动（AF）的非侵入性可穿戴疗法，今日宣布完成其超额认购的3,000万美元A轮融资。本轮融资由John Slump的家族办公室Metis Medtech领投，Catalyst Health Ventures、多家企业战略投资者以及其他新老投资者参与。

The financing is expected to fund StimCardio through its planned NeuroPulse 2 pivotal study as well as the preparation for a De Novo submission to the U.S. Food and Drug Administration (FDA)..

该融资预计将用于支持 StimCardio 开展其计划的 NeuroPulse 2 关键性研究，并为向美国食品药品监督管理局（FDA）提交 De Novo 申请做准备。

Continue Reading

继续阅读

'Our vision is to establish a new therapeutic category in cardiac electrophysiology.' — Amir Soltanianzadeh

“我们的愿景是在心脏电生理学领域开创一个全新的治疗类别。”——阿米尔·索尔塔尼安扎德

Post this

发布此内容

StimCardio Medical's investigational wrist-worn therapeutic device is designed to extend atrial fibrillation treatment beyond the procedure room and into the patient's home, with the goal of reducing arrhythmia recurrence following catheter ablation.

StimCardio Medical 研发的 investigational 腕戴式治疗设备旨在将心房颤动治疗从手术室延伸至患者家中，目标是降低导管消融术后心律失常的复发率。

'Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology,' said Amir Soltanianzadeh, CEO of StimCardio Medical. 'This financing brings together investors with deep expertise in cardiac device innovation and provides the resources to deliver a first-of-its-kind, multicenter pivotal study.

StimCardio Medical 首席执行官 Amir Soltanianzadeh 表示：“我们的愿景是将无创神经调控确立为心脏电生理学中的一个全新治疗类别。本轮融资汇聚了在心脏器械创新领域拥有深厚专业知识的投资者，并为开展一项首创性的多中心关键性研究提供了资源保障。”

With encouraging clinical evidence to date and a growing research program, we see an opportunity to extend treatment beyond the procedure room and improve outcomes for the millions of people living with AF.'.

凭借迄今令人鼓舞的临床证据和不断扩大的研究计划，我们看到有机会将治疗从手术室延伸至更广泛的场景，从而改善数百万房颤患者的预后。

'StimCardio is pioneering innovative technology positioned to disrupt the cardiac electrophysiology arena,' said John Slump, CEO and founder of Metis MedTech and a StimCardio board member. 'Despite decades of advances in catheter ablation procedures, AF recurrence remains a significant unmet clinical challenge.

“StimCardio 正在开创有望颠覆心脏电生理领域的创新技术，”Metis MedTech 首席执行官兼创始人、StimCardio 董事会成员 John Slump 表示。“尽管导管消融手术在过去几十年中取得了诸多进展，但心房颤动（AF）复发仍然是一个尚未满足的重大临床挑战。”

StimCardio has an entirely different approach with a non-invasive wearable that we believe will redefine the treatment paradigm. Our decision to invest reflects our strong conviction in this impressive team, disruptive technology, and growing market.'.

StimCardio 采用了一种截然不同的方法，推出了一款非侵入式可穿戴设备，我们相信这将重新定义治疗范式。我们的投资决定反映了我们对这支卓越团队、颠覆性技术以及不断增长的市场所持有的坚定信念。

Advancing a New Approach to AF Treatment

推进房颤治疗的新方法

According to a 2025 analysis of Global Burden of Disease data published in the

根据2025年对全球疾病负担数据的分析，发表在

Journal of the American College of Cardiology

《美国心脏病学会杂志》

, approximately 59 million people worldwide are living with atrial fibrillation. Catheter ablation is an established treatment for AF and is recommended as a first-line rhythm control therapy for selected patients under the 2023 ACC/AHA/ACCP/HRS clinical guidelines. Despite significant advances in catheter ablation technology, including pulsed field ablation (PFA), recurrent AF remains a persistent clinical challenge.

全球约有5900万人患有心房颤动。导管消融术是治疗房颤的成熟方法，根据2023年ACC/AHA/ACCP/HRS临床指南，被推荐为特定患者的一线节律控制疗法。尽管导管消融技术取得了显著进展，包括脉冲场消融（PFA）的应用，但房颤复发仍然是临床上持续存在的挑战。

Today, approximately .

今天，大约。

30% to 40%

30% 至 40%

of patients experience recurrent AF following an initial ablation procedure.

部分患者在初次消融术后会出现复发性房颤。

StimCardio's lead investigational product, Rhyvive, is a wrist-worn therapeutic wearable designed to deliver personalized, non-invasive median nerve stimulation (MNS) through a closed-loop system that integrates physiological sensing and neuromodulation. Developed as an adjunct to catheter ablation, Rhyvive is designed to extend treatment beyond the procedure and into the patient's home by modulating autonomic nervous system pathways with the goal of reducing recurrent atrial arrhythmias such as AF..

StimCardio 的主要在研产品 Rhyvive 是一款佩戴于手腕的治疗性可穿戴设备，旨在通过集成生理传感与神经调控的闭环系统，提供个性化的无创正中神经刺激（MNS）。Rhyvive 作为导管消融术的辅助疗法而开发，旨在通过调节自主神经系统通路，将治疗从手术期间延伸至患者居家阶段，从而减少心房颤动（AF）等复发性心房心律失常的发生。

'Catalyst Health Ventures invests early in paradigm-shifting technologies with the potential to transform patient care,' said Joshua Phillips, managing partner of

“Catalyst Health Ventures 早期投资于有望变革患者护理的范式转移技术，”管理合伙人 Joshua Phillips 表示

Catalyst Health Ventures

Catalyst 健康风险投资公司

and a StimCardio board member. 'StimCardio's differentiated therapeutic approach targets a significant unmet clinical need affecting a large patient population. Supported by encouraging early clinical evidence, the technology has the potential to reduce AF recurrence following catheter ablation.'

以及StimCardio公司董事会成员。“StimCardio差异化的治疗方法针对的是影响大量患者群体的重大未满足临床需求。在令人鼓舞的早期临床证据支持下，该技术有望降低导管消融术后心房颤动的复发率。”

Building on Clinical Evidence

基于临床证据

The financing follows the presentation of StimCardio's NeuroPulse 1 pilot study as a late-breaking clinical trial at HRX Live 2026 and its peer-reviewed publication in

此次融资紧随StimCardio公司在2026年HRX Live大会上以最新临床试验形式发布的NeuroPulse 1初步研究结果，以及该研究在同行评审期刊上的发表。

Heart Rhythm

心律

. The randomized, double-blind, sham-controlled study demonstrated a statistically significant reduction in recurrent atrial arrhythmia events post-ablation with active MNS stimulation compared with the sham treatment group.

这项随机、双盲、假手术对照研究表明，与假治疗组相比，主动磁导航系统（MNS）刺激可显著降低消融术后复发性房性心律失常事件的发生率，且具有统计学意义。

NeuroPulse 2 will be a major, multicenter pivotal trial designed to evaluate whether adding wearable neuromodulation to catheter ablation improves clinical outcomes compared with ablation alone.

NeuroPulse 2 将是一项大型、多中心的关键性试验，旨在评估与单纯导管消融相比，在导管消融基础上加用可穿戴神经调节技术是否能改善临床结局。

About StimCardio Medical

关于 StimCardio Medical

StimCardio Medical is a clinical-stage medical device company pioneering non-invasive, wearable neuromodulation therapeutics for cardiac rhythm disorders. Its primary investigational technology, Rhyvive, uses median nerve stimulation to target autonomic pathways involved in atrial fibrillation (AF), offering a differentiated approach designed to complement existing cardiac treatments.

StimCardio Medical 是一家处于临床阶段的医疗器械公司，致力于开创用于心律失常的非侵入性可穿戴神经调节疗法。其主要在研技术 Rhyvive 通过刺激正中神经来靶向参与心房颤动（AF）的自主神经通路，提供一种差异化的方法，旨在补充现有心脏治疗手段。

The company's initial clinical focus is improving outcomes following catheter ablation, with a longer-term vision to expand wearable neuromodulation into additional AF and cardiovascular applications. To explore StimCardio's clinical research and publications, visit .

该公司最初的临床重点在于改善导管消融术后的疗效，其长远愿景是将可穿戴神经调控技术拓展至更多心房颤动及心血管领域的应用。如需了解 StimCardio 的临床研究和出版物，请访问 。

stimcardio.com

stimcardio.com

, and follow the company on

，并关注公司的

LinkedIn

领英

for updates.

以获取更新。

About Metis MedTech

关于 Metis MedTech

Metis MedTech is an investment and strategic advisory platform that supports innovative medical device companies through financing, commercialization, and long-term value creation. Led by CEO & Founder, John Slump, the company is built on his track record across four major medical device exits, including two in the cardiac electrophysiology market, Farapulse and Atraverse Medical, representing more than $1.25 billion in aggregate M&A transaction value.

Metis MedTech 是一个投资和战略咨询平台，通过融资、商业化以及长期价值创造来支持创新型医疗器械公司。该公司由首席执行官兼创始人约翰·斯伦普（John Slump）领导，依托他在四次重大医疗器械退出案例中的卓越业绩，其中包括在心脏电生理市场的两个案例——Farapulse 和 Atraverse Medical，累计并购交易价值超过12.5亿美元。

Metis MedTech works with technical founders and physician innovators advancing differentiated technologies in cardiovascular, neurovascular, and other high-impact medical device markets. Founders seeking aligned capital and operator-level partnership may visit .

Metis MedTech 与技术创始人及医师创新者合作，推动心血管、神经血管及其他高影响力医疗器械市场中差异化技术的发展。寻求理念契合资本及运营级合作伙伴关系的创始人可访问。

metismedtech.com

metismedtech.com

.

。

CAUTION: Investigational device. Limited by United States law to investigational use.

注意：研究用器械。根据美国法律，仅限用于研究目的。

Media Contact

媒体联系人

Holly Windler

霍莉·温德勒

619-929-1275

619-929-1275

[email protected]

[email protected]

[email protected]

[email protected]

SOURCE StimCardio Medical Inc.

来源：StimCardio Medical Inc.